Complaint
| Product Name | Tirzepatide Injection |
| Appearance | White powder |
| CAS | 2023788-19-2 |
| Particle Size: | 100% Pass 80 Mesh |
| Function | Weight Loss |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1,
Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.
and reduces glucagon levels, both in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake, 4 and reduce body weight in patients with type 2 diabetes.
Tirzepatide is a once-weekly GIP (glucose-dependent) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity and is currently under regulatory review as a treatment for adults with type 2 diabetes. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF). Studies of tirzepatide in obstructive sleep apnea (OSA) and in morbidity/mortality in obesity are planned as well.
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for
chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2
or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid
condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia).
LIn common to various degrees with other GLP-1 receptor agonists,liraglutide has advantages over more traditional therapies for type 2 diabetes:
1. Liraglutide acts in a glucose-dependent manner, meaning Liraglutide will stimulate insu.lin secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
2. Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. Liraglutide decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
4. Liraglutide lowers blood triglyceride levels.
| Name | CAS No. | Name | CAS No. |
| Thymalfasin | 69440-99-9 | Enfuvirtide (T-20) Acetate | 159519-65-0 |
| Thymopentin Acetate (TP-5) | 69558-55-0 | Angiotensin Acetate | 58-49-1 |
| Octreotide Acetate | 83150-76-9 | Somatostatin | 51110-01-1 |
| Melanotan II Acetate | 121062-08-6 | Vapreotide Acetate | 103222-11-3 |
| Melanotan I Acetate | 75921-69-6 | Dy norphin A (1-13) | 72957-38-1 |
| Secretin Acetate | 17034-35-4 | Leuprolide | 53714-56-0 |
| Ornipressin Acetate | 3397-23-7 | Eledoisin Acetate | 69-25-0 |
| Oxytocin Acetate | 50-56-6 | GLP-1 (7-37) Acetate | 106612-94-6 |
| Lypressin Acetate | 50-57-7 | Pramlintide | Pramlintide |
| Nesiritide Acetate | 114471-18-0 | Aviptadil Acetate | 40077-57-4 |
| Calcitonin (Salmone) Acetate | 47931-85-1 | Exenatide Acetate | 141732-76-5 |
